Authors
Latest:
Clinical Trials in the Community Play Critical Role in Cancer CureJames L. Wade III, MD, FACP, FASCO, discusses the importance of clinical trials in the community.
Latest:
PD-1 Checkpoint Inhibitors in Pretreated Non-Small Cell Lung CancerAn overview of the data and rationale that led to the approval of nivolumab and pembrolizumab for NSCLC, with an emphasis on specific patient populations likely to benefit from this approach and future directions for clinical research in this area.
Latest:
Urine Assay as Test for High-Grade Prostate CancerJames M. Kiernan, MD, professor of Urology and director of Urologic Oncology at NewYork-Presbyterian Hospital/Columbia University Medical Center in New York, discusses EXO106, a urine assay, as a promising test for high-grade prostate cancer.
Latest:
Dr. James Melotek on Cetuximab/Chemotherapy Combinations in Head and Neck CancerMelotek says the trial's primary endpoint was comparison of efficacy when cetuximab is added to both therapies with historical control, with a secondary endpoint being further investigation of the usefulness of both chemotherapy platforms.
Latest:
Updates in NCCN Guidelines for Molecular Testing in Prostate CancerJames Mohler, MD, discusses the rationale for the latest updates to the National Comprehensive Cancer Network guidelines for genetic testing in prostate cancer.
Latest:
Future Immune Checkpoint StrategiesJames P. Allison, PhD, director, immunotherapy platform, The University of Texas MD Anderson Cancer Center, discusses the future of immune checkpoint strategies.
Latest:
Arming an Anti-CD38 Antibody With Interferon in MyelomaJames R. Berenson, MD, discusses a study presented at the 2013 American Society of Hematology (ASH) Meeting that looked at arming an anti-CD38, myeloma-targeting antibody with interferon.
Latest:
Xgeva Approved for Hypercalcemia of MalignancyXgeva (denosumab) has received approval from the US Food and Drug Administration (FDA) for the treatment of hypercalcemia of malignancy (HCM) refractory to bisphosphonate therapy, and the agent was granted Orphan Drug Designation.
Latest:
Impact of a Stage IV NSCLC Care Pathway on Frontline and Maintenance Chemotherapy UseJames Stevenson, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses the impact of a stage IV non-small cell lung cancer (NSCLC) care pathway on frontline and maintenance chemotherapy use.
Latest:
Comparing Treatment Options in Ovarian CancerJames T. Thigpen, MD, discusses the comparison of treatment options in ovarian cancer.
Latest:
Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal EffectsAs a first step toward developing quantitative models, investigators recently developed a mathematical framework to simulate the systemic dissemination of T cells activated in response to focal therapy.
Latest:
Novel Approaches Tackle the JAK Pathway Beyond Ruxolitinib and MyelofibrosisSince the identification of the role of the JAK kinase family in the late 1980s, awareness of this has grown significantly. These tyrosine<br /> kinases have been proven to transmit a variety of signals into the cells with many biological consequences, adding to the interest in the targetability of the JAK pathway. However, better understanding of the complexities of JAK signaling are being evaluated in clinical trials.
Latest:
ATM, CHEK2, and PTEN Genes in Breast CancerJane E. Churpek, MD, medical oncologist, hematologist, The University of Chicago, discusses the ATM, CHEK2, and PTEN genes in breast cancer.
Latest:
Immunotherapies Show Promising Advancements in Small Cell Lung CancerAlthough chemotherapy remains the standard treatment for small cell lung cancer in first- and second-line settings, notable progress in immunotherapies have recently taken place, begging the question of how these agents will be optimized in this tumor type.
Latest:
Identifying and Treating Follicular Lymphoma Patients With Disease ProgressionJane N. Winter, MD, professor of medicine, Division of Hematology/Oncology, Feinberg School of Medicine at Northwestern University, discusses the importance of identifying and treating patients with follicular lymphoma (FL) who experience progression of their disease.
Latest:
The Mechanism of Action of OlaparibJane Robertson, MD, Global Product Vice President at AstraZeneca, describes the mechanism of action of the PARP inhibitor olaparib.
Latest:
Challenges With Finding Biomarkers for ImmunotherapyJanice Mehnert, MD, medical oncologist, director, Phase I and Developmental Therapeutics Program, Rutgers Cancer Institute, discusses the challenges with finding biomarkers for immunotherapy agents.
Latest:
Findings Confirm Opioids Decrease After Restrictive Protocol Takes EffectJaron Mark, MD, gynecologic oncology fellow at Roswell Park Comprehensive Cancer Center, discusses findings from a restrictive protocol that limited the number of opioids prescribed after gynecologic surgeries. Patients looked at in this trial had undergone ambulatory or minimally invasive procedures.
Latest:
Findings of a Study With a Novel Antibody-Drug Conjugate in Ovarian CancerJasgit Sachdev, MD, clinical associate professor at Translational Genomics Research Institute, discusses a recent study of novel antibody-drug conjugate targeting protein tyrosine kinase 7 (PTK7) in ovarian cancer.
Latest:
Exploring Potential HER2-Positive Breast Cancer Treatments for the FutureJasmeet C. Singh, MD, discusses the future of the treatment landscape for HER2-positive breast cancer following positive new research presented at the 2019 San Antonio Breast Cancer Symposium.
Latest:
Ongoing Trials in T-Cell LymphomasJasmine Zain, MD, from the Center for the Lymphoid Malignancies, Columbia University Medical Center, discusses two ongoing trials in T-cell lymphomas.
Latest:
Nadofaragene Firadenovec: Significance of uMRD-Negative Status in Achieving Recurrence-Free Outcomes in NMIBCIn patients with non-muscle-invasive bladder cancer unresponsive to BCG who underwent nadofaragene firadenovec (Adstiladrin) treatment, those who achieved urinary minimal residual disease (uMRD)-negative status showed no recurrences.
Latest:
Trial Designs in Ovarian CancerJason D. Wright, MD, from Columbia University, discusses clinical trial designs in ovarian cancer.
Latest:
Cemiplimab May Be an Effective Treatment for PD-L1+ NSCLC With Brain MetastasesPatients with PD-L1-positive non-small cell lung cancer that has metastasized to the brain did better with cemiplimab plus chemotherapy than with investigator's choice of chemotherapy.
Latest:
The Importance of Research on Rare Subtypes of MelanomaJason J. Luke, MD, assistant professor of medicine at the The University of Chicago Medicine, discusses the importance of conducting research into less common subsets of melanoma. After giving a talk on non-cutaneous melanoma, a rare subtype, Luke explained that not all cases of melanoma arise on the skin and shared why more research is necessary in the field.
